Breaking Finance News

finnCap reiterated Cambridge Cognition Holdings (LON:COG) to Corporate in a report released today.

Displaying a price of 74.50GBX, Cambridge Cognition Holdings (LON:COG) traded 6.94% higher on the day. The last stock price is up 71.56% relative to the 200-day average, compared with the S&P 500 which has fallen -0.01% over the same period. The company has registered a 50-day average of 54.29GBX and 200-day average of 44.88GBX. Trading volume was was down over the average, with 12,425 shares of COG changing hands under the typical 34,931 shares.

finnCap has reiterated Cambridge Cognition Holdings(LON:COG) to Corporate in a statement released 9/20/2016.

On 8/30/2016, finnCap released a statement for Cambridge Cognition Holdings(LON:COG) held the target price at 100.00GBX that suggested an upside of 0.00%.

See Chart Below:

Cambridge Cognition Holdings (LON:COG)

In addition to finnCap reporting it’s target price, a total of 1 analysts has released a report on COG. The 12-month target price is 100.00GBX with 0 rating the stock a strong buy, 0 rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and finally 0 firms rating the company as sell.

Cambridge Cognition Holdings has a one-year low of 30.00GBX and a one-year high of 105.00GBX and has a market capitalization of 0.0 GBX.

About Cambridge Cognition Holdings (LON:COG)

Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company’s segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company’s product, CANTAB Mobile is a Class II medical device, and used to identify patients exhibiting the early signs of Alzheimer’s disease. It also offers Cantab Insight for dementia assessment in secondary care.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *